Lichen Planus Therapeutics Market is driven by growing demand for new line of treatment
The global Lichen Planus therapeutics market is mainly driven by the growing prevalence of lichen planus skin disorder across the globe. Lichen planus is a relatively common inflammatory autoimmune disease that affects the skin, mucous membranes, genitalia and nails and causes itching and discomfort. The exact cause of lichen planus is unknown, but it is believed to be an autoimmune response triggered by various factors such as infection, drugs, or stress. According to estimates, around 1-2% of the general population is affected by lichen planus annually.
Currently, there are limited treatment options available for lichen planus that provide temporary relief from symptoms but do not cure the underlying condition. The existing therapeutic products include topical corticosteroids, topical calcineurin inhibitors, retinoids, antibody therapies and immunosuppressants. However, these therapies are associated with several side effects on prolonged use such as skin thinning, easy bruising, systemic toxicity on oral administration etc. This has created a need for safer and more targeted treatment options for lichen planus patients.
The Global Lichen Planus Market is estimated to be valued at USD 150.1 million in 2024 and is expected to reach USD 251.2 million by 2031, growing at a compound annual growth rate (CAGR) of 7.6% from 2024 to 2031.
The growing prevalence of Lichen Planus Market globally is driving the demand for effective treatment options. According to statistics, lichen planus affects around 1-2% of the general population annually. The increasing patient pool suffering from this chronic skin disorder is boosting the sales of lichen planus therapeutics.
Get More Insights On- Lichen Planus Market
Get this Report in Japanese Language: 扁平紅色苔癬市場
Get this Report in Korean Language: 편평태선 시장
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian